NeoGenomics has made an exciting announcement: its oncology testing services are now integrated with Epic Aura. This means oncologists and health systems across the U.S. can access these tests directly through their Epic electronic health records.
This integration allows doctors to order a wide range of tests that cover solid tumors and blood cancers. They can view results within the same system they already use for patient management. NeoGenomics hopes this will make it easier for hospitals to adopt these tests, potentially increasing their usage by 20-30% at each site.
“Clinicians need quick access to the right diagnostics,” says Tony Zook, CEO of NeoGenomics. He believes that integrating with Epic will help clinicians provide timely treatment, enhancing patient care and making it easier for hospitals to implement precision oncology.
This move is part of NeoGenomics’ strategy to improve connectivity between local oncology practices and larger health systems. It aims to enhance the delivery of modern diagnostic tools, including liquid biopsies, which can detect cancer-related signals in the blood.
Quick access to diagnostic tools can indeed shorten the time from diagnosis to treatment for cancer patients. By placing these capabilities within the existing care delivery systems, NeoGenomics is streamlining the process for everyone involved.
Research shows that timely diagnostics can significantly improve patient outcomes. A recent report indicated that patients who begin treatment within 30 days of diagnosis have a better chance of recovery. This move could very well be a game-changer in how cancer care is delivered.
In today’s digital age, integrating new technologies into healthcare is essential. By combining testing capabilities with electronic health records, NeoGenomics is not just keeping up with the times; it’s pushing the envelope on what’s possible in cancer care.
For more information on digital healthcare innovations, visit HealthIT.gov.
Source link
cancer diagnostics, diagnostic tools, digital health, electronic health records, health systems, laboratory testing, liquid biopsy, molecular residual disease, NeoGenomics, oncology testing, Precision oncology, test adoption,
